Author(s)

Evgeniy I. Volkov¹, Andrei V. Reshetnickov^2,3*, Harrie Vink³

¹State Budget Healthcare Facility “Sverdlovskiy Oblastnoy Oncologicheskiy Dispancer”, Ekaterinburg, Russia.
²AREV PHARM LLC., Moscow, Russia.
³RADA-PHARMA International B.V., Steenbergen, The Netherlands.

Bremachlorin®, also known as “Radachlorin®” and Photochlorin, a composition of 3 chlorophyll a derivatives in an aqueous solution [1], was initially introduced into the Russian and South Korean Pharmacopoeias with the corresponding marketing authorizations received in 2006 and 2008, on the basal cell skin carcinoma PDT protocol. Phase I-II clinical trials led in 2002-2005 showed no side effects, a good tolerability by patients and a high clinical anti-tumor efficacy. Further studies described in the present paper were fulfilled in accordance with a skin melanoma PDT + surgery combined technique protocol in 2006-2016. Resulting from the present trial, up to the 100% complete responses were achieved after resection and plastic surgery following PDT, with no melanoma regrowth or metastases during 5 and 10-year observation periods. Conducting PDT one day prior to tumor dissection can guarantee to meet the ablastics principles at the subsequent surgery. At the same time, the PDT + surgery protocol can allow for dissecting the tumor with less distance from its edge, which seems to be important for the face localizations of tumors.

Melanoma, Skin, PDT, Radahlorin, Radachlorin, Bremachlorin, Photochlorin, Laser, Cancer

Volkov, E. , Reshetnickov, A. and Vink, H. (2017) Melanoma: Surgery Subsequent to PDT—Is It Worth Doing? A 10-Year Pilot Trial Using Chlorin-Type Photosensitizer Bremachlorin^®. Journal of Cancer Therapy, 8, 902-912. doi: 10.4236/jct.2017.810079.